AEP

AEP is a biotechnology company focused on developing novel therapies targeting asparagine endopeptidase (AEP), a key enzyme implicated in the pathogenesis of neurodegenerative diseases. The company's research centers on the role of AEP in cleaving proteins like tau and alpha-synuclein, which leads to the formation of toxic aggregates in conditions such as Alzheimer's and Parkinson's disease. By developing small molecule inhibitors and digital health solutions, AEP aims to provide comprehensive management and treatment options for patients with chronic neurological and metabolic conditions. The company leverages its proprietary platform to identify and optimize drug candidates that can effectively cross the blood-brain barrier and modulate disease progression.